Clinical Trial Update: BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating BI-1206 in combination with an anti-CD20 antibody for CD32b-positive B-cell lymphoma or leukemia; study completed with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Chronic Lymphocytic Leukemia
• Waldenström Macroglobulinemia

Drugs mentioned

• Anti-CD20 antibody
• BI-1206

Snippet

Sponsor: Cancer Research UK | Conditions: B-cell Lymphoma, Chronic Lymphocytic Leukaemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-07-08